ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
A multifunctional hydrogel dressing for wound healing and in vitro cytotoxicity against breast cancer cells: association with GRP78 expression.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Investigating molecular pathways associated with breast cancer progression is important for improving post-surgical therapeutic strategies. Since certain chemotherapeutic agents can activate the unfolded protein response (UPR), with glucose-regulated protein 78 (GRP78) acting as a key regulator of this pathway, this study aimed to develop a post-surgical hydrogel nanocomposite and evaluate its anticancer activity together with its potential effects on GRP78 localization. Chitosan nanoparticles (CsNPs) were synthesized and incorporated into a hydrogel matrix, and the resulting system was characterized using imaging and particle-sizing techniques. Biological evaluations, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on mouse fibroblast NIH/3T3 cells and hemolysis assay, demonstrated acceptable biocompatibility and hemocompatibility of the developed hydrogels. Anticancer investigations in Michigan Cancer Foundation-7 (MCF-7) cells, including MTT assay, apoptosis analysis, intracellular ROS measurement, mitochondrial membrane potential assessment, and caspase activity assay, revealed significant anticancer effects of the nanocomposite. Mechanistic analysis of GRP78 expression further suggested that the hydrogel may promote GRP78 translocation from the cytoplasm to the tumor cell surface, accompanied by increased GRP78 expression, indicating a possible association between GRP78-mediated cellular stress responses and the observed anticancer activity. Overall, these findings support the potential of the developed post-surgical hydrogel nanocomposite as a localized therapeutic platform for breast cancer treatment; however, any direct effects on metastatic behavior remain to be confirmed through dedicated metastasis-related assays.
Indexed as
Identifiers
42726210What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.